Home or hospital care for a blood clot in the lungs
Compares home and hospital care in people with pulmonary embolism.
Key facts
- Who runs it
- University Hospital, Angers
- Where
- France18 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- HOME-PE2 : Home Treatment Versus Hospitalization in Patients With Acute Pulmonary Embolism, no Clinical Severity Criteria, and Either Right Ventricular Dysfunction or Elevated Troponin: a Randomized Controlled Trial
- Status
- Not yet recruiting
- People taking part
- 568 people, planned
- Started
- Jun 2026
- Expected to end
- Sept 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Home treatment
- Hospitalization
- Record updated
- 1 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a new, confirmed blood clot in the lungs (pulmonary embolism) who are not severely ill. They must have either strain on the right side of the heart or a raised troponin heart test. It compares treatment at home with treatment in hospital.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Acute pulmonary embolism with symptoms, confirmed by scan. No signs of severe illness by the Hestia rule (negative Hestia rule). Diagnosed no more than 24 hours ago. Seen in the emergency department or at an unplanned visit.
- Biomarker or test result
- Either right-to-left heart chamber size ratio > 1.0 on heart ultrasound or CT scan, or high-sensitivity troponin I or T above the local upper normal limit. Not both at the same time.
Main reasons for not taking part
- Shock or low blood pressure (systolic below 90 mmHg, or a drop of 40 mmHg or more for more than 15 minutes)
- Both heart strain and raised troponin together, or a loose clot inside the right side of the heart
- Active cancer (other than basal or squamous-cell skin cancer), such as cancer found or treated in the last 6 months, or cancer that has spread
- Pregnant or have just given birth
- Short life expectancy, or 3-month follow-up not possible, or going home within 48 hours of arrival not possible
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Presentation to the Emergency Department or unscheduled consultation in one of the participating centers
- Symptomatic PE objectively confirmed according to the European Society of Cardiology criteria 4 (either by i) a high-probability ventilation/perfusion lung scan, ii) a new contrast filling defect on spiral computed tomography, or iii) a new documentation by ultrasonography of a proximal DVT, i.e., thrombus in the popliteal vein or above, along with clinical signs of PE. All radiological tests used to diagnose PE will be interpreted by on-site radiologists or angiologists)
- No clinical criteria mandating hospitalization according to the Hestia rule, i.e., negative Hestia rule
- Right ventricular dysfunction - defined as a right ventricular (RV) to left ventricular (LV) diameter ratio > 1.0 on echocardiography (apical four-chamber or subcostal four-chamber view) or on CTPA (transverse plane) OR High-sensibility cardiac troponin I or T concentration above the upper limit of local normal value
- Insurance cover according to local legislation
- Age ≥18 years
- Signed free informed consent (or oral consent if possible according to local regulation)
Who cannot take part
- Active cancer other than basal or squamous-cell skin cancer defined at least with one of the following: i) cancer diagnosed within the last 6 months, ii) current anti-cancer treatment or during the 6 months before enrollment, iii) locally advanced or metastatic cancer
- Shock or hypotension (defined as systolic blood pressure <90 mmHg or a systolic pressure drop by ≥40 mmHg, for >15 minutes, if not caused by new-onset arrhythmia, hypovolemia, or sepsis)
- Patient in detention by judicial or administrative decision, under a legal protection measure or undergoing compulsory psychiatric treatment
- Combined right ventricular dysfunction (RV/LV > 1.0 on imaging) AND troponin concentration above the upper limit of local normal value
- Free floating thrombi in the right atrium or ventricle, if identified by routine echocardiography or CTPA
- PE diagnosis established since more than 24 hours
- 48 hours or more elapsed between ED presentation and potential inclusion or other reason making home discharge impossible within the 48 hours since ED presentation
- Limited life expectancy or any other reason making 3-month follow-up impossible
- Pregnant or parturient patient
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study (HOME-PE2) is a multicenter, randomized controlled trial comparing home treatment versus hospitalization in patients with acute pulmonary embolism (PE) who have no clinical severity criteria according to the Hestia rule but present either right ventricular dysfunction or elevated cardiac troponin levels.
Read full original descriptionShow less
While outpatient management is considered safe for low-risk PE patients, the optimal management of patients without clinical severity but with signs of right ventricular strain or myocardial injury remains uncertain, and current guidelines are inconsistent. As a result, most of these patients are still hospitalized despite limited evidence supporting this approach.
The primary objective is to assess whether home treatment is non-inferior to hospitalization in terms of safety, defined by the 7-day rate of adverse events according to the EARTH consensus. Secondary objectives include evaluation of net clinical benefit, quality of life, functional status, and healthcare resource utilization, as well as exploration of sex-related differences and cost-effectiveness.
A total of 568 adult patients with confirmed PE will be randomized (1:1) to either home treatment with early discharge or standard hospitalization. Patients will be followed for 90 days.
The 2 groups in the trial
- Home treatmentTreatment being tested
Patients randomized to this arm are managed as outpatients and discharged early after inclusion, no later than 24 hours after inclusion and no later than 48 hours after presentation to the emergency department. Anticoagulation therapy is initiated prior to discharge and continued in accordance with current guidelines and local practice. Patients receive structured follow-up in accordance with current guidelines and are instructed to seek medical attention in case of clinical deterioration, suspected recurrence of venous thromboembolism, or bleeding.
- HospitalizationExisting treatment, for comparison
Patients randomized to this arm are managed as inpatients and admitted to a hospital medical unit for the management of acute PE according to local organization. Anticoagulation therapy is initiated and managed in accordance with current guidelines and local practice. The duration of hospitalization and timing of discharge are left to the discretion of the treating physician. Patients receive structured follow-up in accordance with current guidelines and are instructed to seek medical attention in case of clinical deterioration, suspected recurrence of venous thromboembolism, or bleeding.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- HOME-PE2 : Home Treatment Versus Hospitalization in Patients With Acute Pulmonary Embolism, no Clinical Severity Criteria, and Either Right Ventricular Dysfunction or Elevated Troponin: a Randomized Controlled Trial
- Plain-language title
- Home or hospital care for a blood clot in the lungsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 1 April 2026